SWP
SAGE

Stratos Wealth Partners’s Sage Therapeutics SAGE Stock Holding History

Stratos Wealth Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-32
Closed -$5K – 2173
2018
Q3 		$5K Buy
+32
New +$4.94K ﹤0.01% 2464
2018
Q2 		– Sell
-182
Closed -$29K – 2255
2018
Q1 		$29K Buy
182
+150
+469% +$25.5K ﹤0.01% 1854
2017
Q4 		$5K Buy
+32
New +$3.1K ﹤0.01% 2400

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Stratos Wealth Partners's SAGE Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Sage Therapeutics (SAGE) in Q4 2018, closing a stake of 32 shares — an estimated $5K sold.

Stratos Wealth Partners first reported a position in SAGE in Q4 2017 and held it in 3 quarters. The position peaked at $29K in Q1 2018. 249 funds tracked by Wall St. Rank hold SAGE as of Q4 2018.

  • Stratos Wealth Partners reported no remaining Sage Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 32 Sage Therapeutics shares in Q4 2018, an estimated $5K.
  • Stratos Wealth Partners first reported a position in Sage Therapeutics in Q4 2017 and held it in 3 quarters.
  • Stratos Wealth Partners's Sage Therapeutics position peaked at $29K in Q1 2018.
  • 249 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.